Efficacy of EGFR Tyrosine Kinase Inhibitors (EGFR TKIs) in Patients With EGFR-mutated Non-small Cell Lung Cancer Except Both Exon 19 Deletion and Exon 21 L859R: A Retrospective Analysis
Observational Model: Case-Only, Time Perspective: Retrospective
the efficacy of EGFR TKIs as defined by objective response rate
up to 1 year
Young Joo Min, M.D.
Ulsan University Hospital
Korea: Food and Drug Administration